IMUX vs INO

Immunic, Inc. vs Inovio Pharmaceuticals, Inc. — Valuation Comparison 2026

IMUX

Pharmaceutical Preparations
Immunic, Inc.
Quality
4.9
out of 10
Value Trap
24
SAFE
Price
$14.96
Last close
Models
7/13
Active
VS

INO

Pharmaceutical Preparations
Inovio Pharmaceuticals, Inc.
Quality
4.3
out of 10
Value Trap
47
WARN
Price
$1.31
Last close
Models
8/13
Active

Model-by-Model Comparison

ModelType IMUX Fair ValueIMUX Upside INO Fair ValueINO Upside
Bayesian DCF Intrinsic $10.51 -29.7% $0.46 -65.0%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $6.42 -57.1% $1.39 +6.2%
Dynamic NAV Asset-Based $19.00 +27.0% $2.08 +58.8%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for IMUX vs INO — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

IMUX vs INO — Which Stock Is More Undervalued?

IMUX scores higher with a 4.9/10 quality rating vs INO's 4.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Immunic, Inc. (IMUX) and Inovio Pharmaceuticals, Inc. (INO) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

IMUX currently trades at $14.96 with a QOC of 4.9/10, while INO trades at $1.31 with a QOC of 4.3/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).